1455results about "Peptide sources" patented technology

The present invention relates to transmissible elements (e.g. conjugative plasmids, phage and phagemid) which are engineered to express molecules of interest (MOIs) and a pathway modification system (PMS) which is able to introduce mutations in target endogenous genes in a recipient bacterium, or is able to produce nucleic acids which inhibit or increase expression of target endogenous genes in a recipient bacterium, or is able to express peptide inhibitor molecules which inhibit a target endogenous protein in a recipient bacterium. The invention relates to host cells containing the transmissible elements, to pharmaceutical compositions containing such transmissible elements or host cells, and their use in the treatment of various diseases.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a base editing system for optimizing engineered T cells and application of the base editing system. The present invention provides a base editing system for modifying engineered T cells, comprising: i) a base editing polypeptide, and / or an expression construct encoding a base editing polypeptide, the base editing polypeptide comprising a DNA binding protein and at least one deaminase domain; ii) a guide RNA, and / or an expression construct encoding a guide RNA, the guide RNA targeting any one of TRAC, TGFBR2, PD-1, CISH, and / or FAS genomic regions, or any combination thereof. The base editing system disclosed by the invention has high efficiency of a gene editing tool and low Indel frequency, can realize accurate editing of T cell function enhancement related genes, and has important value for expanding application scenes of a base editing technology in the fields of preparation of safe and efficient engineered T cells and the like.

The present invention relates to a p75NTR neurotrophin binding protein, p75NTR (NBP), for use in the treatment of pain and / or a symptom of pain.

The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

The invention belongs to the fields of gene engineering, bioengineering and biological medicine, and relates to a nucleic acid molecule for coding human defensin, a method for preparing the human defensin and application. The nucleic acid sequence of the nucleic acid molecule comprises any one of the following sequences: (1) a sequence as shown in SEQ ID NO.2; (2) a nucleic acid sequence for coding human defensin, which is obtained by substituting, deleting or adding one or more than two nucleotides to the sequence as shown in SEQ ID NO.2; and (3) a nucleotide sequence which has at least 80% sequence homology with the nucleotide sequence in (1) or (2) and has the same or similar functions with the nucleotide sequence in (1) or (2). According to the method provided by the invention, the recombinant expression vector is constructed by using nucleic acid molecules for coding the human defensin, the human defensin hBD-3 can be recombined and expressed, the recombinant fusion protein is released to the supernatant of a culture solution, the protein purification is convenient, the obtained recombinant human defensin has a tissue regeneration function, and a new active molecule is provided for the development of a novel drug.

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a system, a tool and a method for modifying or editing target nucleotide bases, and more specifically, the invention relates to an optimized QBE base editing system and application thereof. The base editing system disclosed by the invention has the advantages of high efficiency of a gene editing tool, high product purity, low Indel frequency, low off-target frequency and abundant gene editing windows, and has important value for expanding application scenes of a base editing technology in the fields of life science basic research, agriculture, biological medicine and the like.

To provide polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, and further to provide methods of making and using the same.SOLUTION: Provided are: polypeptides including specific sequences or an amino acid sequence that is at least 90% identical to an amino acid sequence of any combination thereof; or a polypeptide including specific sequences or an amino acid sequence of any combination thereof. In some embodiments, an FN3 domain does not naturally exist. In some embodiments, the FN3 domain binds to human CD71 at a site on CD71 that does not compete with transferrin binding to CD71.SELECTED DRAWING: None

The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts antithrombotic effects. The antibody of the present invention has suitable antithrombotic properties, has a wide effective therapeutic concentration window, but does not increase the risk of bleeding; it can realize the demand for moderate antithrombotic properties in clinical applications and effectively avoid bleeding problems caused by excessive effects. The present invention also discloses a method for screening drugs that target the FIXa-FVIIIa binding site.

A non-integrating viral delivery system is disclosed. The system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

A compound comprising a prostate-specific membrane antigen (PSMA) targeting moiety of the following formula: R 0 is O or S. 1a , R 1b and R 1c Each of R may be, for example, —COH, —SOH, —SOH, —POH, or —POH. 2 R may be an optionally substituted methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene. 3 is a linker. When the PSMA targeting moiety is attached to a radiolabeling group, the compound may be used as an imaging agent or a therapeutic agent for diseases / conditions that express PSMA. TIFF2022537773000240.tif2237

The present invention relates to modified bacteria and plasmids (e.g., conjugate plasmids) engineered to express indole-3-acetic acid (IAA), pharmaceutical compositions containing the same and their use in the treatment of various metabolic and cardiovascular diseases.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and / or NK cells. The methods can include inhibitory RNA molecule(s) and / or engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and / or genetically modified T cells and / or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and / or pH-modulating agents.

Disclosed is a novel classification of conjugate virus-like particles (VLPs). These conjugate VLPs conjugate to a wide variety of tumors and contain epitopes that are recognized by past T-cell responses already present in the host's body. These epitopes originate from pathogens or past vaccinations (such as early childhood vaccines). This triggers pre-existing cytotoxic immunity in the body acquired through past infection or past childhood vaccination, which is redirected to tumor cells for tire elimination of cancer and forms long-term anti-tumor immunity. The described conjugate VLPs are useful in adapting a wide range of tumors to responses from existing immunity, bypassing the need to identify tumor antigens or generate tumor-specific immune responses. Importantly, the compositions and methods described herein expand opportunities for treating affected cancer types in subjects with a history of cancer that could not be targeted due to various technical and biological limitations of currently available immunotherapeutic agents.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and / or clearance in tissues, receptor uptake and / or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and / or modulation of a cell's status, function, and / or activity.

Provided are cell models of eye diseases, methods and compositions for treating eye diseases.

The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and / or NK cells, in shorter times than previously and / or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

The present inventions provide covalently surface modified adeno-associated viruses can comprise gene of interest (GOIs) and advantageously can be targeted to certain cell and tissue types for preventative and therapeutic purposes. The present inventions further provide systems and methods for engineering adeno-associated virus (AAV) to create covalently surface modified adeno-associated viruses, and methods of purifying such covalently surface modified adeno-associated viruses. The inventions further include covalently surface modified adeno-associated viruses and preparations and products comprising such covalently surface modified adeno- associated viruses.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to modified bacteria and plasmids (e.g. conjugative plasmids) which are engineered to express auxins and auxin-like molecules (ALMs), to pharmaceutical compositions containing them and their use in the treatment of various metabolic and cardiovascular diseases.

The present invention finds the effect of ATXN2 and / or ATXN2L in circadian rhythm. Thus, the present invention provides methods, medicaments and uses for modulating circadian rhythm in a subject. Meanwhile, the invention further provides a method for detecting the circadian rhythm of a subject and a biomarker capable of indicating circadian rhythm abnormity. The invention provides a brand new way and means for adjusting the circadian rhythm.

The invention provides a method for rejuvenating cells by reprogramming in a phase-free separation transcription factor mediated initiation stage. Through improvement of phase-free separation of transcription factors, a recombinant vector is constructed and introduced into a target cell, and the cell is controlled in a reprogramming starting stage, so that the technical effect of rejuvenation is achieved.

The invention provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and application. In the first aspect, the invention provides a glycosyl-modified fusion protein which comprises a mouse Fc variant and a prostatic cancer tumor antigen, the mouse Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a mouse Fc fragment; the mouse Fc variant comprises at least one of alanine at the 223 site, alanine at the 228 site, alanine at the 230 site, leucine at the 330 site and glutamic acid at the 332 site; the non-mammalian glycosylation modification does not comprise sialic acid modification; the site numbering is carried out according to an EU numbering system; the mouse Fc variant improves combination of a mouse Fc fragment and DC cells and DC activation, including proliferation and activation of specific T cells.

The present invention relates to a method for making a non-human primate model of cerebral infarction comprising a step of administering endothelin to the brain basal nucleus-thalamic region of a non-human primate, thereby inducing brain basal nucleus disorders, thalamic disorders and endocystic disorders, and a method for treating subacute stages-containing NeuroD1 protein or a polynucleotide encoding a NeuroD1 protein The pharmaceutical composition can be used for treating chronic cerebral infarction, transbronchial infarction or cerebral infarction with brain disorder in a transbronchial dominating region.

Disclosed herein are plant messenger packs (PMPs) encapsulating one or more exogenous polypeptides. Also disclosed are methods of producing a PMP comprising an exogenous polypeptide.

The present invention provides an agent capable of modulating variable splicing in the intron of the SLC20A2 gene, and its use for modulating the expression of functional PiT2 protein to prevent and / or treat disease. The invention further provides a brain calcification model based on variable splicing in the intron of the human SLC20A2 gene, a preparation method of the brain calcification model, and application of the model to indication and analysis of the incidence stage of brain calcification, or to a model for researching phosphorus homeostasis imbalance in brain or a target of brain calcification, or to screening of drugs.